Accelerated brain volume loss (BVL) starts in the early stages of MS and is associated with accumulating physical and cognitive disability.^[@R1][@R2][@R5]^ In a recent meta-analysis of clinical trials including patients with relapsing-remitting MS, treatment effects of disease-modifying therapies (DMTs) on BVL showed a strong correlation with treatment effects on disability worsening over 2 years.^[@R6]^

In 2 phase 3 pivotal trials (TEMSO, NCT00134563, and TOWER, NCT00751881), teriflunomide 14 mg (AUBAGIO, Genzyme, Cambridge, MA), a once-daily oral immunomodulator approved for relapsing-remitting MS,^[@R7][@R8][@R9]^ significantly reduced the risk of 12-week confirmed disability worsening (CDW) in patients with relapsing MS.^[@R10],[@R11]^ A significant reduction in annualized relapse rate in both studies and a reduction in MRI activity in TEMSO were also reported (no MRI was performed in TOWER).^[@R10][@R11][@R12]^ BVL was assessed in TEMSO by changes in brain parenchymal fraction (BPF) using an MRI analysis package (MRIAP), developed and performed at UTHealth, Houston, TX. The results demonstrated numerical reduction of BVL by ∼25% with teriflunomide 14 mg vs placebo, but this was not statistically significant.^[@R12]^ The MRIAP method has had limited use in successful large phase 3 studies in MS; therefore, it is difficult to assess its sensitivity for detecting change and therapeutic effects across different DMTs. Structural image evaluation using normalization of atrophy (SIENA) is a well-established, longitudinal, registration-based technique with a low error rate in detecting brain volume changes over time.^[@R13],[@R14]^

Given the consistent and statistically significant effects of teriflunomide on reducing the risk of disability worsening, and the strong association between BVL and disability worsening in MS, a new masked analysis of TEMSO MRI was undertaken using SIENA.

METHODS {#s1}
=======

Standard protocol approvals, registrations, and patient consents. {#s1-1}
-----------------------------------------------------------------

The TEMSO study ([ClinicalTrials.gov](http://ClinicalTrials.gov) identifier NCT00134563) was conducted in accordance with the International Conference on Harmonisation Guidelines for Good Clinical Practice and the Declaration of Helsinki. The protocol was approved by central and local ethics committees and the respective institutional review board; patients provided written informed consent before entering the study.

Study design. {#s1-2}
-------------

TEMSO was a 2-year, phase 3, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy and safety of teriflunomide in reducing the frequency of relapses and progression of physical disability in patients who had relapsing MS, as reported previously.^[@R10]^ After a screening phase of up to 4 weeks, eligible patients were randomly assigned (in a 1:1:1 ratio) to receive a once-daily oral dose of placebo, 7 mg of teriflunomide, or 14 mg of teriflunomide for 108 weeks.

The primary objective of the SIENA reanalysis of the TEMSO MRI data set was to evaluate the effect of teriflunomide vs placebo on BVL from baseline to year 1 and year 2.

MRI analysis. {#s1-3}
-------------

MR scans collected from the TEMSO study^[@R12]^ at baseline and at weeks 48 (year 1) and 108 (year 2) were analyzed using the SIENA method, as performed at the Medical Image Analysis Center (MIAC AG, Basel, Switzerland). Further details of the specific SIENA methodology used for this analysis are provided in the supplementary material.

SIENA was applied to 3-mm thick precontrast T1-weighted images of a 70-mm central brain area section (Montreal Neurological Institute Z coordinates −10 to +60 mm), which was selected for optimal reproducibility and comparability to previous trials of other oral DMTs.^[@R15][@R16][@R21]^ MR images of 2 time points were coregistered, and surface changes were determined using the fully automated algorithm to estimate brain volume changes (figure e-1 at [Neurology.org/nn](10.1212/NXI.0000000000000390)).

In addition, the single-point SIENA cross-sectional method (SIENAX)^[@R13]^ was also applied to the T1-weighted images to estimate the normalized whole-brain volume of each patient at baseline (figure e-2).

Study personnel were masked to treatment allocation and other study data. A rigorous quality control of all uploaded MRI data and all stages of the SIENA analysis was performed. This led to the exclusion of some scans for 1 or more of the following reasons: required MRI sequence(s) for the evaluation were missing, quality of MRI sequence(s) was insufficient for the evaluation, and reference or longitudinal follow-up MRI was missing or excluded from the analysis for one of the aforementioned reasons.

Statistical analysis. {#s1-4}
---------------------

The change from baseline in annualized percentage brain volume was analyzed, and median (95% CI) values were determined for each treatment group. Treatment group comparisons were made via nonparametric analysis of covariance, adjusted for region, age, Expanded Disability Status Scale (EDSS) strata, and normalized brain volume (using SIENAX). A similar method was applied for treatment group comparisons in a subgroup analysis of BVL in patients with or without on-study CDW, defined as an increase from baseline of at least 1.0 point in the EDSS score (or at least 0.5 points for patients with a baseline EDSS score greater than 5.5) that persisted for at least 12 or 24 weeks. The relationship between CDW and BVL was evaluated using a Cox model with CDW as the dependent variable and BVL as the independent variable, together with other covariates (treatment and stratification factors used for randomization). As this SIENA analysis was a masked reanalysis, but not a prospectively defined analysis as per the TEMSO protocol, no formal adjustment for multiplicity was performed.

Classification of evidence. {#s1-5}
---------------------------

This study provides Class II evidence of reduction in BVL, as assessed by masked SIENA analysis, over 2 years of treatment with once-daily oral teriflunomide 7 mg or 14 mg, compared with placebo, in patients with relapsing forms of MS.

RESULTS {#s2}
=======

Patients. {#s2-1}
---------

At each time point, ≥89.5% of the patient scans included in the original MRI analysis of the TEMSO study (described as the TEMSO MRI population below) were deemed suitable for inclusion at the corresponding time point in the SIENA analysis: 969 patients had baseline MRI; 808 had baseline and year 1 MRI (scans from 95/903 patients \[10.5%\] with evaluable MRI in the TEMSO MRI population, were excluded at year 1, before SIENA analysis); and 709 had baseline and year 2 MRI (scans from 69/778 patients \[8.9%\] were excluded at year 2). The mean (SD) normalized brain volume values at baseline for those patients included in the SIENA analysis were similar between the 3 treatment groups: 1,508.9 cm^3^ (77.9 cm^3^), 1,507.8 cm^3^ (83.1 cm^3^), and 1,502.7 cm^3^ (75.8 cm^3^), for placebo and teriflunomide 7 and 14 mg, respectively (*p* = 0.5610; for the comparison between groups of baseline normalized brain volume).

Baseline demographics and clinical characteristics of patients included in the SIENA analysis were similar to those of patients in the previously published TEMSO MRI population ([table](#T1){ref-type="table"}), including between-treatment comparisons (data not shown). Furthermore, the annualized relapse rate was consistent between both populations with respect to the comparison between placebo-treated patients (TEMSO MRI population: 0.517; SIENA: 0.509) and between patients treated with teriflunomide 14 mg (TEMSO MRI population: 0.343; SIENA: 0.330). The percentage of patients with CDW was also comparable within the placebo-treated patients (TEMSO MRI population: 25.2%; SIENA: 23.6%) and the teriflunomide 14 mg--treated patients (TEMSO MRI population: 18.8%; SIENA: 19.8%) in both study populations. These data demonstrate that the exclusion of a small number of scans, due to stringent quality control as done for the SIENA analysis, did not bias the final outcomes.

###### 

Patient demographics and baseline clinical characteristics^a^

![](NEURIMMINFL2017012682TT1)

SIENA analysis. {#s2-2}
---------------

At both time points analyzed, teriflunomide 7 and 14 mg significantly slowed BVL compared with placebo ([figure 1A](#F1){ref-type="fig"}). The difference in BVL with teriflunomide at year 1 (vs placebo) was maintained at year 2. Analysis of BVL in patients with MRI for all 3 time points (i.e., baseline, year 1, and year 2) demonstrated a similar pattern ([figure 1B](#F1){ref-type="fig"}).

![Annualized percentage brain volume change\
Annualized median percentage change from baseline in BVL over 2 years for teriflunomide 14 and 7 mg vs placebo: (A) using all scans available at each time point; (B) for patients with complete scan series at all time points. BVL = brain volume loss; CI = confidence interval; \*Relative change vs placebo.](NEURIMMINFL2017012682FF1){#F1}

In a sensitivity analysis, exclusion of patients who had been included in the original TEMSO MRI population (assessed using MRIAP) but who did not have MRI data of sufficient quality for the SIENA analysis did not affect the overall findings. This was demonstrated by similar patterns of brain volume changes (as assessed by changes in BPF using MRIAP) between the groups analyzed: those to be included in the new SIENA analysis only, those included in the original TEMSO MRI population only, and those excluded from the new SIENA analysis (figure e-3).

Relationship between on-study disability worsening and BVL. {#s2-3}
-----------------------------------------------------------

In a Cox model, BVL over 2 years had an effect on CDW: risk reduction of 11% for every 1% change in brain volume (*p* = 0.0203).

The normalized brain volume at baseline was lower in the patient subgroup with subsequent on-study disability worsening vs the subgroup without disability worsening. At baseline, patients with and without 12-week CDW had mean (SD) brain volumes of 1,495 cm^3^ (83.4 cm^3^) and 1,509 cm^3^ (77.6 cm^3^), respectively; *p* = 0.02. Patients with and without 24-week CDW had brain volumes of 1,493 cm^3^ (86.7 cm^3^) and 1,509 cm^3^ (77.5 cm^3^), respectively; *p* = 0.03.

Placebo-treated patients demonstrated increased rates of BVL if they also had on-study disability worsening vs those without worsening ([figure 2A](#F2){ref-type="fig"}). Of note, BVL remained statistically significantly lower in patients treated with teriflunomide 14 mg than in placebo-treated patients, regardless of the presence or absence of on-study disability worsening at both years 1 and 2 ([figure 2, B and C](#F2){ref-type="fig"}). The median percentage change from baseline in patients treated with teriflunomide 14 mg with vs without on-study 12-week CDW at year 1 was −0.25 vs −0.40 (*p* = 0.48), respectively, and at year 2 was −0.90 vs −0.87 (*p* = 0.68), respectively.

![BVL according to on-study disability worsening\
BVL according to on-study disability worsening in (A) placebo-treated patients with and without 12- or 24-week confirmed disability worsening (CDW); (B) placebo- and teriflunomide 14 mg--treated patients with 12- or 24-week CDW; (C) placebo- and teriflunomide 14 mg--treated patients without 12- or 24-week CDW. BVL = brain volume loss; CI = confidence interval. \*Relative change vs patients without CDW; \*\*Relative change vs placebo.](NEURIMMINFL2017012682FF2){#F2}

A similar pattern of reduced BVL was observed in patients receiving teriflunomide 7 mg, although results did not reach statistical significance in the subgroup of patients without 12- or 24-week CDW from baseline to year 2 (figure e-4, A and B).

DISCUSSION {#s3}
==========

Limiting BVL in MS is increasingly recognized as an evolving and important therapeutic goal, despite challenges of measurement at an individual patient level. The importance of BVL is due, in part, to the recognized association between BVL and long-term accumulation of physical and cognitive disability, which reduce both patients\' functional ability and their quality of life. Accelerated BVL can be evident from the earliest stages of MS, which highlights the need for early and effective intervention.^[@R1],[@R22],[@R23]^ In this masked reanalysis of the TEMSO MRI data set using the SIENA method, teriflunomide significantly slowed BVL vs placebo, an effect that was maintained to the end of the TEMSO core study.

SIENA is a well-established longitudinal registration-based technique with a low error rate in detecting brain volume changes over time^[@R13],[@R14]^ and has been repeatedly used to measure treatment effects on brain atrophy with oral DMTs other than teriflunomide.^[@R15][@R16][@R21]^ SIENA can outperform many cross-sectional methods regarding sensitivity and reproducibility^[@R13],[@R24]^ and, thus, may be better suited for this purpose.^[@R12]^

This analysis of TEMSO MRI using the SIENA methodology was conducted using the same procedures as in other phase 3 studies of oral DMTs,^[@R15][@R16][@R21]^ with study personnel masked to treatment allocation and other study data. By applying rigorous quality-control criteria, some TEMSO MRIs were excluded in this reanalysis. It is acknowledged that exclusion of scans as a result of rigorous quality-control has the potential to introduce selection bias. Nonetheless, a sensitivity analysis demonstrated that exclusion of some TEMSO MRI did not affect baseline or other characteristics of the patients assessed.

The significant reduction in BVL observed in this analysis is consistent with the positive effect of teriflunomide on disability worsening already initially observed in a phase 2 study and later confirmed in both phase 3 studies: TEMSO and TOWER, which compared teriflunomide with placebo in patients with relapsing forms of MS.^[@R10],[@R11],[@R25]^ Our additional analysis showing faster rates of BVL in placebo-treated patients with on-study disability worsening compared with those without worsening provides further evidence that greater BVL is related to an increased risk of disability worsening. On-study disability worsening may also reflect the clinical manifestations of accumulated BVL before the start of the TEMSO study, as evidenced by lower baseline brain volumes in the subgroup with disability worsening vs the subgroup without. Nevertheless, treatment with teriflunomide was associated with a significant reduction in BVL, regardless of the presence of on-study disability worsening, suggesting that teriflunomide exerts this effect in a broad range of patients with MS.

In a meta-analysis of data from 13 randomized clinical trials evaluating DMTs in patients with RRMS, the size of the treatment effect on brain atrophy was closely correlated with the size of treatment effect on 2-year disability worsening at the trial level (*R*^2^ = 0.48).^[@R6]^ The meta-analysis included the data from the original MRIAP analysis of BPF changes conducted in TEMSO.^[@R12]^ When the 13-trial meta-analysis was repeated, replacing the MRIAP analysis of TEMSO MRI with the SIENA analysis of BVL, the *R*^2^ values for the treatment effect correlation between brain atrophy and disability worsening strengthened from 0.48 to 0.61.^[@R26]^

Preservation of brain volume with teriflunomide is consistent with its proposed mechanism of action in MS. The primary mechanism of action of teriflunomide is believed to relate to the reversible inhibition of proliferation of activated T and B lymphocytes, thereby limiting their involvement in damaging processes within the CNS.^[@R27]^ Studies of teriflunomide administered to rats with experimental autoimmune encephalitis (EAE) at disease onset showed reduced lymphocyte counts in the rats\' spinal cords.^[@R28]^ EAE animals dosed therapeutically with teriflunomide showed reduced CNS inflammation, reduced disease scores, reduced axonal damage and demyelination, and preserved sensory and motor neuronal function compared with untreated EAE animals.^[@R29],[@R30]^ However, whether these results are driven solely by the anti-inflammatory effects of the drug acting in the periphery is currently unclear. Evidence is emerging that teriflunomide is found in the CNS at pharmacologically relevant concentrations and that teriflunomide treatment in vitro has direct effects on activated rodent microglia and astrocyte functions,^[@R31]^ suggesting that teriflunomide may have potential neuroprotective effects within the CNS, at least in rodents.

In this new analysis, teriflunomide---an immunomodulatory DMT with established efficacy on annualized relapse rate, disability worsening, and MRI lesion activity---has been demonstrated to reduce BVL. This result---besides indicating a neuroprotective potential of teriflunomide---further strengthens the evidence of a link between BVL and disability worsening.

Supplementary Material
======================

###### Data Supplement

Supplemental data at [Neurology.org/nn](10.1212/NXI.0000000000000390)
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BPF

:   brain parenchymal fraction

BVL

:   brain volume loss

CDW

:   confirmed disability worsening

DMT

:   disease-modifying therapy

EAE

:   experimental autoimmune encephalitis

EDSS

:   Expanded Disability Status Scale

MRIAP

:   MRI analysis package

SIENA

:   structural image evaluation using normalization of atrophy

SIENAX

:   SIENA cross-sectional method
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